"Pharmaceutical Express" Mercadon and Seattle co-operation well-known pharmaceutical companies to buy six varieties

September 15, 2020 / Medical Information At a Glance: Blainger Ingham and Click collaborated in the development and commercialization of CT-155; JAK inhibitors/Redsivir combination therapy reached phase 3 clinical endpoints; Sanofi/regenerative dupixent treatment of acidic granulocytic esophagealitis was recognized by the FDA breakthrough therapy; assapen Pharmaceuticals 3 products were eligible for FDA orphan drugs... Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Briefing The National Health And Health Commission issued a new coronavirus pneumonia prevention and control program (7th edition) in order to further guide all regions to do a good job in the prevention and control of new coronavirus pneumonia, in a comprehensive summary of the epidemic prevention and control work experience, combined with the national epidemic situation changes and research progress, the State Council to respond to the new coronavirus pneumonia epidemic joint prevention and control mechanism integrated group organization revised the "new coronavirus pneumonia prevention and control program."
(National Health and Health Commission) National Health and Safety Commission: Strengthen the management of narcotic drugs in medical institutions and the first category of psycho-drugs The National Health and Safety Commission issued a notice on strengthening the management of narcotic drugs and psycho-drugs in medical institutions, aimed at strengthening the management of narcotic drugs and first-class psycho-drugs in medical institutions, ensuring reasonable clinical needs, and strictly preventing the flow of illegal channels.
(National Health and Safety Commission) CDE issued the "Overseas production of drugs re-registration declaration procedures, declaration information requirements and form review content" in accordance with the "State Drug Administration on the implementation of the drug registration management measures related matters", in order to promote the relevant supporting normative documents, technical guidelines drafting and formulation work, under the deployment of the State Drug Administration, CDE formulated "overseas production of drugs re-registration declaration procedures, declaration information requirements and form review content", is now issued from January 2020.
(CDE) Shanghai medical supplies (artificial crystal class) centralized procurement of the results of the proposed selection of shanghai pharmaceutical centralized bidding procurement services announced by the Shanghai medical supplies (artificial crystal class) centralized procurement of the results of the proposed selection. according to the
announcement, september 15, 2020 to September 18, 2020 is the public notice period, if there are any objections, please before the public notice deadline to the Shanghai Pharmaceutical Centralized Tendering and Procurement Service Management Institute to file a complaint and provide legal and valid evidence materials, overdue will not be accepted.
provide the corresponding evidence material, it shall not be accepted in principle.
(Shanghai Sunshine Procurement Network) a batch of drugs in Guizhou suspended for Guizhou Province Public Resources Trading Center issued a notice on the 14th, canceling some drugs winning the bid (hanging net) qualification notice.
According to the document, some enterprises due to production line transformation, production stoppage and other reasons, drugs have been unable to guarantee supply, submitted an application to cancel their products in Guizhou Province drug centralized procurement of the winning bid (hanging net) qualification, and promised that from the date of cancellation, the enterprise with the same product regulations products for two years may not participate in the centralized procurement activities of drugs in Guizhou Province.
A total of 22 drugs were disqualified from winning the bid (hanging net), and are basically large varieties, including injectable antonin, cephalosporinecapsules, raw pulse drinks, involving Taiji Group Chongqing Chinese Medicine Co., Ltd., Southwest Pharmaceutical Co., Ltd., Suzhou Second Leaf Pharmaceutical Co., Ltd. and other well-known pharmaceutical companies.
(Guizhou Provincial Public Resources Trading Center) pharmacy attention for the second category of psycho-drugs began on the 14th, Liaoning Provincial Drug Administration issued the "provincial drug regulatory bureau to carry out the second type of psycho-drug operation special inspection work" announcement, in order to further strengthen the second category of psycho-drug purchase and sale management, strictly prevent the flow of abuses occurred, the provincial drug regulatory bureau inspection six in conjunction with the actual Dandong region, organized to carry out the second category of psycho-drug operation special inspection.
(Liaoning Provincial Drug Administration) Part 2 after observation Ofadong and Seattle Genetics reached a joint agreement Seattle Genetics and Mercer East jointly announced that the two sides reached two strategic oncology cooperation.
, the two companies will jointly develop and promote the antibody-coupled drug ladiratuzumab vedotin, which targets LIV-1, worldwide in a partnership.
(Pharmaceutical) Grigg Ingham and Click co-developed and commercialized CT-155 Grigg Ingham and Click Therapeutics recently announced a partnership to jointly develop and commercialize a prescription digital therapy CT-155.
under the terms of the cooperation agreement, Click will be primarily responsible for research and development activities and will provide support in the global commercialization of GriggIngham.
will receive an advance and research funding, as well as clinical, registration and commercial milestone payments, totaling more than $500 million.
(American News Agency) Fangsheng Pharmaceuticals 7 million yuan to buy six large varieties recently, Fangsheng Pharmaceuticals announced that Fangsheng Pharmaceuticals and Hunan Kangjia Pharmaceutical signed a "drug variety transfer agreement." according to the
announcement, Fangsheng Pharmaceuticals decided to transfer the ownership of six drug varieties, such as "intestinal capsules", "vitamin C bubble particles", "through pulse oral solution", "six-flavored yellow capsules", "silver yellow particles" and "A gum sanbao paste" for RMB7 million.
Neogene received $110 million in financing today, and Neogene announced the completion of a $110 million round of A-round financing, led by EcoR1 Capital, Jeito Capital and Syncona, with Polaris Partners and Pontifax also involved.
(Xinhua) -- NiKang completed a $50 million round of B financing on Thursday, and NiKang announced the completion of a $50 million round of B financing led by RTW Investments, with additional support from new investors such as Lilly Asia Fund, Casdin Capital, HBM Healthcare Investments, Matrix Partners China and Octtagon Capital.
proceeds will be used to support the preclinical and clinical development of promising oncology programs and to further improve the company's drug development channels.
(Pharma Mission) Part 3 Drug News Novartic Next Generation Anti-VEGF Ophthalmology Drug Reaches the Key Endpoint of Phase 3 Research 14, Novarma announces the results of a key Phase 3 study on the treatment of diabetic macular edema (DME) patients with the new generation of anti-VEGF ophthalmology drug Beovu.
study showed that the trial reached the primary and critical secondary endpoints, and beovu achieved non-poor results compared to controlled drugs in the average change in optimal corrective vision in year 1.
(Pharmaceutical Mission) JAK Inhibitor/Redsiway Combination Therapy Phase 3 Clinical Endpoint Lilly and Incyte announced that its JAK inhibitors Baricitinib and Redsivir are used in combination to reach the main endpoint of the trial in the adaptive Phase 3 clinical trial ACT-2 sponsored by the National Institute of Allergy and Infectious Diseases.
compared to Redsiweiser, baricitinib and Redsiweiser can shorten patient recovery time.
drug, Mallinckrodt, was denied approval by the FDA, which rejected An application for Mallinckrodt Terripressin to treat rare, in-patient renal failure.
the drug had previously achieved its main objectives in Phase 3 and had won the support of the Advisory Committee.
fda believes more information is needed to support the benefits of Terrigamin in patients with hepatitis 1 and kidney syndrome outweigh the risks.
(Sina Pharmaceutical News) Sanofi/ Regenerative Dupixent treatment of eosinophilic esopheditis was recognized by the FDA breakthrough therapy on the 14th, the U.S. FDA has awarded Sanofi / Regenerative Dupixent breakthrough treatment designation for the treatment of 12 years of age and older eosinophilic esophpathy (EoE) patients.
this finding is based on positive results from Phase 3 clinical trial Part A in EoE patients.
tests reached two main end points, as well as all the key secondary endpoints.
the 24-week treatment period, patients who took 300 mg of Dupixent per week had reduced symptoms, inflammation of the esoptosis and abnormal results from endoscopy of the esoptosis.
(Sina Pharmaceutical News) Yasheng Pharmaceuticals 3rd product harvest FDA orphan drug qualification Asheng Pharmaceuticals announced on the 14th that the U.S. FDA awarded its independent research and development of the original innovative drug APG-115 orphan drug qualification, used for the treatment of stomach cancer.
This is the first time that APG-115 has been granted orphan drug qualification by the FDA, it is the 3rd drug of Asaan Pharma to be qualified as an FDA orphan drug, and the fourth consecutive qualification of orphan drug obtained from the FDA in less than 6 months.
(Pharmaceutical Rubik's Cube) shore-based bio-double immunoassist inhibitors in the United States approved clinical shore-based biology announced that its new EMB-02 clinical application received the FDA "clinical research can start" confirmation letter.
EMB-02, which also targets immunochesin proteins PD-1 and LAG-3, is the second self-developed new dual-specific antibody candidate for solid tumor therapy.
(Pharmaceutical Mission) Johnson and Johnson EGFR-MET dual-anti-3rd generation EGFR-TKI combination therapy approved in China 4 clinical CDE publicity, Johnson and Johnson EGFR-MET dual anti-drug amivantamab injection and 3rd generation EGFR-TKI drug lazertinib tablet combination therapy obtained 4 clinical trials acquiesced license, adaptation: for the treatment of EGFR 19 external absence or 8L NSCLC patients with 8R-activated mutations who develop the disease after first- or second-generation TKI or first- or second-line treatment with first- or second-generation TKI;
(Pharmaceutical Mission) Sansheng Pharmaceuticals announced that the Beval Pearl single anti-biosimilar drug China IND was accepted on the 14th, Sansheng Pharmaceuticals announced that the application for the IND of the Beval pearl single anti-biosimilar drug SB8 has been accepted by the China Drug Administration.
under a cooperation agreement announced with Samsung Bioepis on January 7, 2019, Sansheng will be responsible for the clinical development and commercialization of the product in Chinese mainland excluding Hong Kong, Macau and Taiwan.
-like drug beval beads in China will target metastatic colorectal cancer and non-small cell lung cancer.
(AAP) Zhong Nanshan Team: Human recombinant granulocyte collection stimulation factors to reduce the death of specific new coronary patients recently, Zhong Nanshan academician team in the Journal of the American Medical Association - Internal Medicine published the results of human recombinant granulocyte collection stimulation factor (rhG-CSF) in the new coronavirus disease accompanied by lymphocyte reduction but no merger of patients in randomized controlled clinical trial results.
showed that rhG-CSF may have reduced the number of patients with severe illness or death in these patients.
(Medical New View point)